Dr. Patrick Forde, MD
Claim this profileJohns Hopkins University/Sidney Kimmel Cancer Center
Area of expertise
Lung Cancer
Patrick Forde, MD has run 7 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Patrick Forde, MD has run 5 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Johns Hopkins University/Sidney Kimmel Cancer Center
Johns Hopkins University
Clinical Trials Patrick Forde, MD is currently running
Biological Specimen Collection
for Head and Neck Cancers
This trial collects samples from cancer patients to study how their immune system responds to treatments. It focuses on patients with tumors in the head, neck, chest, and upper digestive system. By analyzing these samples, researchers aim to improve cancer therapies and predict side effects.
Recruiting
1 award
N/A
2 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
More about Patrick Forde, MD
Clinical Trial Related
11 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Patrick Forde, MD has experience with
- Durvalumab
- Carboplatin
- Nivolumab
- Paclitaxel
- Pembrolizumab
- Lobectomy
Breakdown of trials Patrick Forde, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Mesothelioma
Malignant Pleural Mesothelioma
Head and Neck Cancers
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Patrick Forde, MD specialize in?
Patrick Forde, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage II patients, or patients who are Stage I.
Is Patrick Forde, MD currently recruiting for clinical trials?
Yes, Patrick Forde, MD is currently recruiting for 2 clinical trials in Baltimore Maryland. If you're interested in participating, you should apply.
Are there any treatments that Patrick Forde, MD has studied deeply?
Yes, Patrick Forde, MD has studied treatments such as Durvalumab, Carboplatin, Nivolumab.
What is the best way to schedule an appointment with Patrick Forde, MD?
Apply for one of the trials that Patrick Forde, MD is conducting.
What is the office address of Patrick Forde, MD?
The office of Patrick Forde, MD is located at: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland 21287 United States. This is the address for their practice at the Johns Hopkins University/Sidney Kimmel Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.